论文部分内容阅读
目的通过培养人微血管内皮细胞(HMEC-1)及建立鸡胚尿囊膜模型(CAM)观察重组人血管抑素(rhAS)的生物学活性。方法将不同浓度的rhAS加入含HMEC-1的培养瓶中,培养48h后,用MTT法检测其对细胞的抑制率;用乙酰胆碱酯酶(AchE)的活性测定检测rhAS诱导HMEC-1凋亡的作用;用CAM模型检测rhAS对血管的抑制作用。结果 rhAS在体外可显著抑制HMEC-1细胞的增殖;在体内则可明显抑制CAM上血管的生成。通过AchE活性测定,发现rhAS既可抑制HMEC-1细胞的增殖,也可诱导HMEC-1细胞凋亡,其作用的不同与rhAS剂量相关。结论 rhAS是一个较有前景的抗肿瘤血管药物。
Objective To observe the biological activity of recombinant human angiostatin (rhAS) by culturing human microvascular endothelial cells (HMEC-1) and establishing chick embryo allantoic membrane (CAM) model. Methods Different concentrations of rhAS were added into culture flasks containing HMEC-1. After cultured for 48 hours, the inhibitory rate of rhAS was detected by MTT assay. The apoptosis of HMEC-1 cells was detected by the activity of acetylcholinesterase (AchE) The inhibitory effect of rhAS on blood vessels was detected by CAM model. Results rhAS could significantly inhibit the proliferation of HMEC-1 cells in vitro and inhibit the formation of blood vessels on CAM in vivo. Through the AchE activity assay, rhAS was found to both inhibit the proliferation of HMEC-1 cells and induce the apoptosis of HMEC-1 cells. The effect of rhAS was related to rhAS dose. Conclusion rhAS is a more promising anti-tumor vascular drugs.